Ublituximab (intravenous form) is a medication that targets specific cells in the immune system. It is administered through a vein and is used in the treatment of multiple sclerosis. This medication works by reducing the number of certain immune cells that may be involved in causing inflammation and damage to the nervous system.

Ublituximab (subcutaneous form) is the same medication but administered as an injection under the skin. This form is being tested to see if it works as effectively as the intravenous version while potentially offering more convenience to patients with multiple sclerosis.

Multiple Sclerosis (Relapsing Form) – A chronic neurological condition affecting the central nervous system, where the immune system attacks the protective covering of nerve fibers. In the relapsing form, patients experience episodes of new or worsening symptoms (relapses) followed by periods of partial or complete recovery (remissions). During relapses, patients may experience various symptoms including vision problems, muscle weakness, balance issues, and fatigue. The disease typically shows a pattern of relapses and remissions, with symptoms varying among individuals. Between relapses, patients may experience relatively stable periods with minimal or no progression of symptoms.